Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

This study has been completed.
Sponsor:
Information provided by:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT00865605
First received: March 17, 2009
Last updated: August 13, 2010
Last verified: August 2010
  Purpose

The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).


Condition Intervention Phase
Healthy
Drug: Halobetasol Propionate 0.05% Ointment, single exposure
Drug: Ultravate® 0.05% ointment, single exposure
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Official Title: A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study

Resource links provided by NLM:


Further study details as provided by Actavis Inc.:

Primary Outcome Measures:
  • Primary outcome: Vasoconstrictor Response [ Time Frame: 36 hours ] [ Designated as safety issue: No ]

Enrollment: 71
Study Start Date: December 2003
Study Completion Date: July 2004
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Halobetasol Propionate 0.05% Ointment, single exposure
Drug: Halobetasol Propionate 0.05% Ointment, single exposure
A: Other Subjects received Alpharma/Purepac USHP formulated products
Other Name: Halobetasol
Active Comparator: B
Ultravate® 0.05% ointment, single exposure
Drug: Ultravate® 0.05% ointment, single exposure
Subjects received Bristol-Myers Squibb Company formulated products
Other Name: Halobetasol

Detailed Description:

Study Type: Interventional Study Design: A single blind, single-exposure study on healthy adult male and female subjects.

Official Title: A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Vasoconstrictor Response

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject understands the study, is willing to participate, and gives written informed consent.
  • Subject demonstrates adequate vasoconstriction to the screening topical corticosteroid Halobetasol propionate 0.05% ointment within 30 days of dosing.
  • Subject is a non-smoking (minimum of 14 days), male or female, ages of 18 - 65 years, inclusive.
  • Subject is within 20% of their ideal body weight as defined by the 1999 Metropolitan Life Insurance Company Height and Weight Tables.
  • Subject is judged by the Investigator to be healthy on the basis of pre-study medical history.
  • Subjects of child-bearing potential agree to use an acceptable method of birth control during study participation (e.g. abstinence, any prescribed birth control method, double barrier method, Le. condom plus foam, condom plus diaphragm).
  • Subject is willing to refrain from excessive consumption of sodium in food or beverage 48hrs before and for the duration of the study.
  • Subject is willing to shower using the same soap/cleansers for the duration of the study.
  • Subject is willing to follow study restrictions.

Exclusion Criteria:

  • Subject has a past or current medical condition that might significantly affect pharmacodynamic response to topical corticosteroids.
  • Subject has diabetes mellitus, clinically significant hypertension or circulatory disease.
  • Subject is taking any medication on a regular basis that could modulate blood flow (constrictor or dilator), with the exception of any prescribed birth control method and hormone replacement therapy. Examples of such drugs include nitroglycerin, anti- hypertensives, antihistamines, NSAIDs, aspirin, phenylpropanolamine, phentolamine or any other medications deemed inappropriate by the Investigator.
  • Subject is planning to use any exclusionary over-the-counter (OTC) medications within 48 hours prior to or throughout the study that could modulate vascular blood flow.
  • Subject intends to start, stop or change dose of any prescription or OTC medication within 48 hours prior to or throughout the study. Acetaminophen may be administered, if needed.
  • Subject has used prescription or OTC topical medications on the ventral forearms within 1 month prior to study conduct.
  • Subject has a history of sensitivity/allergy to the ingredients found in the test formulations or has a history of adverse reactions to topical or systemic corticosteroids.
  • Subject has a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
  • Subject has a history of significant skin conditions or disorders, for example, psoriasis, atopic dermatitis, etc.
  • Subject has a history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma. Basal cell carcinomas that were superficial and do not involve the investigative site are acceptable.
  • Subject has an obvious difference in skin color between arms or the presence of a skin condition, scar tissue, tattoo or coloration that would interfere with placement of test sites, their assessments, their reaction to drug or could compromise the safety of the subject.
  • Subject has used topical medications on the ventral forearms within 1 month prior to dosing.
  • Subject has used a tobacco product within 14 days of study conduct.
  • Subject has a clinically significant history of drug abuse or alcoholism.
  • Subject has donated or received blood within 30 days prior to dosing.
  • Subject's caffeine intake is greater than 500 mg per day (1 cup of coffee contains approximately 85 mg of caffeine).
  • Subject is unwilling to abstain from alcohol or caffeine for 48 hours prior to and throughout the study.
  • (Females only): Subject is pregnant or lactating.
  • Subject has participated in another investigational drug, medical device, or biologics study within 30 days prior to dosing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00865605

Locations
United States, California
DermTech International
San Diego, California, United States, 92128
Sponsors and Collaborators
Actavis Inc.
Investigators
Principal Investigator: Paul A. Lehman,, M.Sc. DermTech International
  More Information

Additional Information:
No publications provided

Responsible Party: Christine Winslow, Director of Clinical Development, Actavis Inc
ClinicalTrials.gov Identifier: NCT00865605     History of Changes
Other Study ID Numbers: DP03-689
Study First Received: March 17, 2009
Last Updated: August 13, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Actavis Inc.:
bioequivalence
Vasoconstriction
Halobetasol
Healthy subjects

Additional relevant MeSH terms:
Halobetasol
Clobetasol
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 20, 2014